Compounds > 1-anilino-8-naphthalenesulfonate

Page last updated: 2024-10-21

1-anilino-8-naphthalenesulfonate and Retinal Neovascularization

1-anilino-8-naphthalenesulfonate has been researched along with Retinal Neovascularization in 2 studies

1-anilino-8-naphthalenesulfonate: RN given refers to parent cpd
8-anilinonaphthalene-1-sulfonic acid : A naphthalenesulfonic acid that is naphthalene-1-sulfonic acid substituted by a phenylamino group at position 8.

Retinal Neovascularization: Formation of new blood vessels originating from the retinal veins and extending along the inner (vitreal) surface of the retina.

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Maguire, MG	1
Ying, GS	1
Jaffe, GJ	1
Toth, CA	1
Daniel, E	1
Grunwald, J	1
Martin, DF	1
Hagstrom, SA	1
Gao, S	1
Li, C	1
Zhu, Y	1
Wang, Y	1
Sui, A	1
Zhong, Y	1
Xie, B	1
Shen, X	1

Clinical Trials (1)

Trial Overview

Trial			Phase	Enrollment	Study Type	Start Date	Status
Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial (CATT)[NCT00593450]			Phase 3	1,208 participants (Actual)	Interventional	2008-02-29	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Area of Lesion

(NCT00593450)
Timeframe: at 1 Year

Intervention	mm^2 (Mean)
1-Lucentis Monthly	6.6
2-Avastin Monthly	6.5
3-Lucentis as Needed	7.3
4-Avastin as Needed	7.0

Area of Lesion Change From Baseline

(NCT00593450)
Timeframe: Baseline and 1 Year

Intervention	mm^2 (Mean)
1-Lucentis Monthly	-0.1
2-Avastin Monthly	0.3
3-Lucentis as Needed	0.6
4-Avastin as Needed	1.3

Average Cost of Drug/Patient

(NCT00593450)
Timeframe: at 1 Year

Intervention	US dollars per patient (Mean)
1-Lucentis Monthly	23400
2-Avastin Monthly	595
3-Lucentis as Needed	13800
4-Avastin as Needed	385

Change From Baseline in Visual-acuity Score (Continuous)

"Visual acuity testing was performed with the Electronic Visual Tester (EVA) following the ETDRS protocol. VA score is measured as number of letters read correctly. The VA score change is the difference of the VA score at 1 Year and the VA score at baseline.~In this study, the outcome VA score change is ranged from -71 to 52, with the higher VA score change the better visual acuity improvement." (NCT00593450)
Timeframe: Baseline and 1 Year

Intervention	No. of Letters (Mean)
1-Lucentis Monthly	8.5
2-Avastin Monthly	8.0
3-Lucentis as Needed	6.8
4-Avastin as Needed	5.9

Change in Diastolic Blood Pressure From Baseline

(NCT00593450)
Timeframe: Baseline and 1 Year

Intervention	mm Hg (Mean)
1-Lucentis Monthly	-0.9
2-Avastin Monthly	-1.4
3-Lucentis as Needed	-1.9
4-Avastin as Needed	-2.1

Change in Systolic Blood Pressure From Baseline

(NCT00593450)
Timeframe: Baseline and 1 Year

Intervention	mm Hg (Mean)
1-Lucentis Monthly	-2.1
2-Avastin Monthly	-5.4
3-Lucentis as Needed	-5.2
4-Avastin as Needed	-4.5

Number of Treatments

Cumulative over the 1 year of trial (NCT00593450)
Timeframe: 1 Year

Intervention	Number of Treatments (Mean)
1-Lucentis Monthly	11.7
2-Avastin Monthly	11.9
3-Lucentis as Needed	6.9
4-Avastin as Needed	7.7

Retinal Thickness Plus Subfoveal-fluid Thickness at Fovea

(NCT00593450)
Timeframe: at 1 Year

Intervention	μm (Mean)
1-Lucentis Monthly	152
2-Avastin Monthly	172
3-Lucentis as Needed	166
4-Avastin as Needed	172

Retinal Thickness Plus Subfoveal-fluid Thickness Change From Baseline at Fovea

(NCT00593450)
Timeframe: Baseline and 1 Year

Intervention	μm (Mean)
1-Lucentis Monthly	-100
2-Avastin Monthly	-79
3-Lucentis as Needed	-81
4-Avastin as Needed	-79

Total Thickness at Fovea

(NCT00593450)
Timeframe: at 1 Year

Intervention	μm (Mean)
1-Lucentis Monthly	266
2-Avastin Monthly	300
3-Lucentis as Needed	294
4-Avastin as Needed	308

Total Thickness Change From Baseline at Fovea

(NCT00593450)
Timeframe: Baseline and 1 Year

Intervention	μm (Mean)
1-Lucentis Monthly	-196
2-Avastin Monthly	-164
3-Lucentis as Needed	-168
4-Avastin as Needed	-152

Visual-acuity Score and Snellen Equivalent (Continuous)

"Visual acuity testing was performed with the Electronic Visual Tester (EVA) following the ETDRS protocol. VA score is measured as number of letters read correctly.~In this study, the outcome VA score is ranged from 0 to 97, with the higher score the better visual acuity." (NCT00593450)
Timeframe: at 1 Year

Intervention	No. of Letters (Mean)
1-Lucentis Monthly	68.8
2-Avastin Monthly	68.4
3-Lucentis as Needed	68.4
4-Avastin as Needed	66.5

Change From Baseline Visual-acuity Score (Frequency)

(NCT00593450)
Timeframe: Baseline and 1 Year

,,,

Intervention	Participants (Number)
	Increase of ≥15 letters	Increase of 5-14 letters	Change of ≤4 letters	Decrease of 5-14 letters	Decrease of ≥15 letters
1-Lucentis Monthly	97	90	62	19	16
2-Avastin Monthly	83	98	50	18	16
3-Lucentis as Needed	71	103	75	23	13
4-Avastin as Needed	76	90	59	23	23

Dye Leakage on Angiogram

(NCT00593450)
Timeframe: at 1 Year

,,,

Intervention	Participants (Number)
	Absent	Present	Data missing
1-Lucentis Monthly	167	97	20
2-Avastin Monthly	153	100	12
3-Lucentis as Needed	133	137	15
4-Avastin as Needed	111	145	15

Fluid on Optical Coherence Tomography

(NCT00593450)
Timeframe: at 1 Year

,,,

Intervention	Participants (Number)
	Absent	Present	Data missing
1-Lucentis Monthly	124	151	9
2-Avastin Monthly	69	188	8
3-Lucentis as Needed	68	203	14
4-Avastin as Needed	52	214	5

Visual-acuity Score and Snellen Equivalent (Frequency)

(NCT00593450)
Timeframe: at 1 Year

,,,

Intervention	Participants (Number)
	83-97 letters, 20/12-20	68-82 letters, 20/25-40	53-67 letters, 20/50-80	38-52 letters, 20/100-160	≤37 letters, ≤20/200
1-Lucentis Monthly	42	149	52	23	18
2-Avastin Monthly	45	134	47	21	18
3-Lucentis as Needed	38	141	66	23	17
4-Avastin as Needed	40	127	57	24	23

Trials

1 trial available for 1-anilino-8-naphthalenesulfonate and Retinal Neovascularization

Article	Year
Single-Nucleotide Polymorphisms Associated With Age-Related Macular Degeneration and Lesion Phenotypes in the Comparison of Age-Related Macular Degeneration Treatments Trials. JAMA ophthalmology, 2016, Jun-01, Volume: 134, Issue:6 Topics: Aged; Aged, 80 and over; Complement C2; Complement C3; Complement Factor B; Complement Factor H; Cro	2016

Other Studies

1 other study available for 1-anilino-8-naphthalenesulfonate and Retinal Neovascularization

Article	Year
PEDF mediates pathological neovascularization by regulating macrophage recruitment and polarization in the mouse model of oxygen-induced retinopathy. Scientific reports, 2017, 02-17, Volume: 7 Topics: Animals; Cell Hypoxia; Cell Polarity; Cells, Cultured; Disease Models, Animal; Eye Proteins; Human U	2017